Abstract
Introduction: Amphotericin B (AmB) is still the first-line therapy for neonatal fungal infections. Recently, lower renal and hematologic toxicity profiles have been observed for Intralipid-based Amphotericin B(IL-AmB) in critically ill patients. Based on initial empirically observed benefits of this admixture in selected neonates, we reviewed the renal tolerance and infection outcome in low birthweight infants treated with IL-AmB in our NICU.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
